TMPRSS2-ETS fusion prostate cancer: biological and clinical implications
- 1 November 2007
- journal article
- editorial
- Published by BMJ in Journal of Clinical Pathology
- Vol. 60 (11) , 1185-1186
- https://doi.org/10.1136/jcp.2007.046557
Abstract
Commentary on the paper by Rajput et al (see page 1238)Keywords
This publication has 21 references indexed in Scilit:
- Cancer Statistics, Trends, and Multiple Primary Cancer Analyses from the Surveillance, Epidemiology, and End Results (SEER) ProgramThe Oncologist, 2007
- 25-Year Prostate Cancer Control and Survival Outcomes: A 40-Year Radical Prostatectomy Single Institution SeriesJournal of Urology, 2006
- Long-Term Outcome Following Radical Prostatectomy in Men With Clinical Stage T3 Prostate CancerJournal of Urology, 2006
- Three-Color FISH Analysis of TMPRSS2/ERG Fusions in Prostate Cancer Indicates That Genomic Microdeletion of Chromosome 21 Is Associated with RearrangementNeoplasia, 2006
- How Well Does the Gleason Score Predict Prostate Cancer Death? A 20-Year Followup of a Population Based Cohort in SwedenJournal of Urology, 2006
- TMPRSS2:ETV4 Gene Fusions Define a Third Molecular Subtype of Prostate CancerCancer Research, 2006
- Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancerGenes, Chromosomes and Cancer, 2006
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005
- Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptomeOncogene, 2005
- The Long-Term Clinical Impact of Biochemical Recurrence of Prostate Cancer 5 or More Years After Radical ProstatectomyJournal of Urology, 2003